| 名稱(chēng) | EGFR L858R-T790M-C797S/BaF3 |
| 型號(hào) | CBP73049 |
| 報(bào)價(jià) | ![]() |
| 特點(diǎn) | EGFR L858R-T790M-C797S/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO |
產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
- 一起認(rèn)識(shí)下腫瘤細(xì)胞的遷移性
- TROP2靶點(diǎn)藥物爆發(fā),診斷質(zhì)控緊跟步伐--科佰TROP2 IHC質(zhì)控品上新
- 實(shí)驗(yàn)?zāi)芊裰貜?fù)仍在持續(xù):誰(shuí)來(lái)給韓春雨事件畫(huà)上句號(hào)?
- 抑制性檢查點(diǎn)靶點(diǎn)及其細(xì)胞篩選模型
- 腫瘤細(xì)胞的四大原代培養(yǎng)方法闡述
- 科學(xué)家如何深度破解癌癥基因組的奧秘?
- 41BB——T細(xì)胞共刺激新靶點(diǎn)
- BRAF系列標(biāo)準(zhǔn)品
- 拯救偏頭痛!CGRP及其受體拮抗劑研究進(jìn)展
- 【連載-企業(yè)參考品】胃腸道間質(zhì)瘤的PCR和NGS參考品的選擇
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73049EGFR L858R-T790M-C797S/BaF3
- 詳細(xì)內(nèi)容
| CBP73049 | |
| I. Introduction | |
Cell Line Name: | EGFR L858R-T790M-C797S/BaF3 |
Host Cell: | Ba/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
| II.Background | |
EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors. | |
| III. Representative Data | |
1. WB of EGFR-L858R/T790M/C797S expression | |
| |
Figure 1. WB of EGFR Expression Lane 1: Negative control Lane 2: EGFR-WT Lane 3: EGFR-L858R/T790M Lane 4: EGFR-L858R/T790M/C797S | |
2. Sanger sequencing | |
| |
Figure 2. Sanger Sequencing of EGFR-L858R/T790M/C797S | |
3. Anti-proliferation assay | |
| |
Figure 3. Anti-proliferation assay of three reference compounds on the EGFR L858R-T790M-C797S/BaF3 Stable Cell Line | |








會(huì)員_a.png)